Together, these data suggest that further investigations of BDP1 expression in serous ovarian cancer are warranted, specifically in the context of additional muations such as TP53 to determine how dual‐expression of BDP1 potentially contributes to serous ovarian cancer. The gene discussed is TP53; the disease is ovarian serous adenocarcinoma.